Thought Leadership
The economics of waiting lists
Why backlogs behave less like queues and more like shadow prices in modern health systems
Waiting lists are usually described in operational terms: too many patients, not enough capacity, inefficient processes, winter pressures, staff shortages. These factors matter, but they disguise a more fundamental truth.
In advanced health systems, waiting lists behave less like queues and more like prices, a hidden economic mechanism that shifts the cost of system imbalance onto patients rather than confronting it within the system itself.
This is an uncomfortable idea because it reframes waiting not as failure, but as an allocation tool.
In markets, scarcity produces price increases. In health systems, scarcity produces time delays. One is a monetary cost; the other is a temporal one. Both ration access. Both reveal structural mismatches between supply and demand. Both expose the limits of institutional capacity.
The challenge is not simply that waiting lists are long. It is that they function as the default currency through which systems manage overload.
Economists have long recognised that when a service’s price cannot adjust, time becomes the rationing mechanism. In publicly funded systems where monetary pricing is constrained, waiting functions as a form of shadow price. It is not an accident of poor management, but a signal of imbalance between demand and institutional capacity.
The signal is stark: the volume of care a population needs has outpaced the institutional capacity of systems to deliver it. Not clinical capacity alone, but institutional capacity, which includes planning bandwidth, scheduling sophistication, administrative coordination, governance depth, and the ability to reorganise supply in response to fluctuating demand.
When institutional capacity fails to adjust, waiting times absorb the shock.
This is why waiting lists rise across very different health systems simultaneously, in the NHS, in Canada, in Australia, in Scandinavian countries that otherwise perform well. Despite different levels of funding, staffing and digitalisation, they face the same arithmetic: demand rising at 2 to 4 percent per year, capacity lagging, and institutions struggling to adapt fast enough.
Time becomes the balancing variable.
The conventional narrative treats waiting lists as an operational backlog. But backlogs behave more like capital stock than episodic pressure.
They accumulate, persist, generate “interest” in the form of complications, and require more effort to clear as they age. Long waits convert mild conditions into moderate ones, moderate into severe, and severe into emergencies.
The economic consequences are enormous. OECD estimates suggest that productivity losses from untreated or delayed conditions cost between 2 percent and 5 percent of GDP across advanced economies.
These are not intangible numbers. Musculoskeletal delays reduce labour participation. Cataract wait times affect workplace safety. Mental health backlogs feed long-term unemployment. Chronic disease delays produce downstream hospitalisations.
Waiting is not free. It is simply paid for later and elsewhere, by patients, employers, social systems and future NHS budgets.
The health system avoids the cost upfront but pays a larger one down the line. Waiting lists therefore resemble intertemporal debt: a borrowing of present capacity from future wellbeing.
A second misunderstanding is the belief that clearing a backlog is a time-limited effort, a form of operational spring-cleaning.
Governments announce elective recovery drives, surgical accelerators, rapid response theatres, weekend blitzes. These programmes generate political momentum and local improvement. But they fail for a simple economic reason: they treat flows as if they were stocks.
Backlogs form when inflow persistently exceeds outflow. Clearing the stock without altering the flow guarantees reaccumulation.
This is not a management problem. It is a structural equilibrium.
Unless systems adjust underlying throughput, efficiency and demand-management mechanisms, waiting lists will revert to prior levels.
This explains why waiting times in the NHS fell dramatically after the 2000s investment surge, when both capacity and institutional focus rose, and why they increased again when institutional attention shifted and demand resumed its trajectory.
Waiting lists are states of equilibrium, not temporary anomalies.
A third misconception is the idea that adding capacity alone will solve the problem.
Additional theatres, diagnostic hubs, surgical robots and community clinics can help. But capacity without coordination produces diminishing returns.
Health systems today resemble supply chains with weak synchronisation. A hospital may expand surgical capacity only to discover bottlenecks in pre-operative assessment or post-operative recovery. Diagnostic hubs may accelerate imaging but overwhelm specialists who interpret scans. Community services may increase throughput but face delays in social-care transitions.
In economic terms, systems face coherence constraints, not only capacity constraints.
Each unit of added capacity produces full value only when embedded in a coordinated sequence. Without that embedding, marginal gains shrink rapidly and waiting lists persist.
This is why countries that have reduced waiting times sustainably did not only invest. They reorganised.
Denmark redesigned referral pathways. Sweden strengthened care coordination and national prioritisation tools. New Zealand sequenced investment with institutional reform.
These systems did not simply add supply. They redesigned the architecture of access.
A more subtle dynamic concerns the political economy of waiting.
Public systems are under pressure to remain equitable. They cannot ration through price, so they ration through time. Yet time is not equitable. It penalises those who cannot take time off work, arrange childcare or travel long distances. It disproportionately harms people in unstable jobs, people with chronic illnesses and those living in regions where supply is structurally lower.
This creates a quiet regressive tax: the people who wait longest are often those whose economic resilience is weakest. Meanwhile, private insurance, self-pay options and cross-border care allow those with means to bypass the queue.
Waiting lists, born as instruments of fairness, often reproduce inequality. Not by design, but by structural gravity.
A final misconception is the belief that waiting lists can be addressed institution by institution.
Backlogs accumulate across the entire system. They reflect mismatches between primary care access, diagnostic throughput, specialist availability, hospital capacity, community recovery and social-care coordination. Each segment acts as a partial constraint.
Treating waiting lists as a hospital issue is like treating traffic congestion as a problem of a single road.
The solution requires system-wide adjustments:
demand-shaping strategies
prioritisation frameworks
scheduling optimisation
coherent digital triage
coordinated capacity expansion
stable, long-term institutional focus
Systems that manage waiting times successfully are not those that work harder. They are those that work in alignment.
The economics of waiting lists leads to a different conclusion from the usual debate.
Backlogs are not signs of sudden failure or seasonal misfortune. They are price signals of health systems that have outgrown their institutional architecture.
Reducing waiting times sustainably requires more than operational effort or temporary investment. It requires redesigning the mechanisms through which systems manage scarcity, coordinate capacity and absorb rising demand.
The currency of waiting is not measured only in minutes or months. It is measured in what gets deferred, health, productivity and dignity, and in what it reveals: a system balancing itself through time because it no longer knows how to balance itself through design.
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.